When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was incredulous. I remember at night, my wife and I pricking his heel, and saying No, this cant be, this cant be, he says. It felt like we had lost the lottery.
Later, his daughter would receive the same diagnosis. By then, Melton had already dropped what he was doingstudying frog eggs at Harvardand launched an effort to grow pancreatic cells from scratch in his lab. The beta cells of the pancreas are the ones killed off in type 1 diabetes, and Melton reasoned he could replace them using new tissue manufactured from embryonic stem cells.
Meltons effort, involving a 30-person lab at Harvard and a startup company, Semma Therapeutics, which he named after his children, Sam and Emma, is one of the most costly and sustained efforts to turn stem cells into transplantable tissue, an attempt that Melton admits has been full of false starts and dead ends. The public definitely doesnt appreciate that much of science is failure, he says.
In fact, no field of biotechnology has promised more and delivered less in the way of treatments than embryonic stem cells. Only a handful of human studies has ever been carried out, without significant results. The cells, culled from IVF embryos, are capable of developing into any other tissue type in the body, and therefore promise an unlimited supply of replacement tissue.
Sounds simple, but it hasnt been. It took Melton and his team 15 years to unveil each molecular step required to coax a stem cell into a pancreatic beta cell able to sense glucose and secrete insulin. The recipe uses a cocktail of chemicals and a three-dimensional incubation system, tall spinning flasks brewing what looks like murky red Gatorade, that within 30 days can direct the differentiation of stem cells into fully functional beta cells.
Earlier this year, Melton was finally able to demonstrate he could control blood glucose levels of mice for six months using transplants of human beta cells. He thinks he can do that in humans and stretch the therapeutic effect out to a year, a goal thats been turned over to Semma, which is designing an implantable pouch to hold and protect the cells.
Over the last two years, Semma has raised just under $50 million from venture capital firms, California's stem-cell agency, and corporate partners including Novartis and Medtronic. William Sahlman, a Harvard Business School professor who sits on Semma's board, says people are prepared to put very large amounts of money on the experiments. One reason: the global market for insulin exceeds $30 billion a year. Tests strips and monitors might double that.
Because their bodies mount an immune attack on the pancreatic cells that regulate blood glucose, type 1 diabetics are constantly measuring their blood sugar levels with finger pricks and injecting insulin multiple times a day. Their lives can be foreshortened by more than a decade. You could almost say that cellular therapy is the natural solution, Melton says. Its not the technological solution. Its not the Google solution. Its natures solution to the problem. Youre providing the cell which is missing.
Several companies are attempting a tech solution, however, by using electronics to build an artificial pancreas that combines a continuous glucose monitor, an insulin pump, and a sensor with an algorithm to control dosing. Medtronic is nearing FDA approval with one such closed loop system; its smartphone-sized MiniMed 670G performed well in early trials. One of Googles sister companies, Verily, is itself developing glucose-sensing contact lenses and ultra-thin sensors.
San Diego-based ViaCyte, working with Johnson & Johnson, was first to try pancreatic cells derived from embryos in people. It has built an implantable packet of immature cells, which it hopes will differentiate inside the body, and last year opened a clinical trial to test the idea.
Semma also thinks it needs to turn embryonic stem cells into not only insulin-secreting beta cells, but a full-fledged isletthe cluster of cells that includes the alpha, beta, delta, and ancillary cells normally found in a pancreas. Thats a complex objective but one that closely mimics biology. Theres a reason during evolution that these cells are adjacent to one another, says Felicia Pagliuca, Semma's cofounder and a veteran of Meltons lab.
In order to deliver their lab-grown islet to diabetics, Semma is developing prototypes of an iPhone-sized, retrievable packet whose materials insulate it from the immune system, so that patients dont have to take immune-suppressing drugs, as they would if they had a kidney transplant. Christopher Thanos, Semma's vice president of delivery, says his team is modeling physiological processes inside and around the device to experiment with different rates of oxygen, nutrients, and insulin diffusion.
Some outside experts think protecting the cells will not be possible. I'm not optimistic that encapsulation is going to provide the answer, says David Cooper, a professor of surgery at the University of Pittsburgh working on growing human islets in pigs. I personally don't think a device is ever going to be successful. It's impossible to keep all the injurious agents out, he says, referring to the cytokines, antibodies, and other compounds the body releases in response to a foreign body. There's really very little evidence that a capsule can protect you completely from an immune response.
The prospect of surgery every year for the rest of your life is also a practical concern. How many diabetics would sign up for 50, 60, 70 surgeries over the course of a lifetime? What will be the effect of repeated scarring around the surgical site? Melton says the inconvenience of surgery has to be weighed against the thousands of finger pricks and injections that diabetics must administer every year. My kids say once a month they wouldnt hesitate. I think thats a bit extreme, he says. But if it was twice a year, I think thats a go.
If the device does not work, Semma has a backup plan of sorts. It received a $5 million grant from CIRM, the California stem-cell agency, to manufacture islets out of a patient's own tissue using induced pluripotent stem cells. That is a process by which adult cells, like skin cells, are reprogrammed into stem cells. Such matching cells wouldnt be rejected by the body as foreignand might not need as much protectionalthough they probably would not avoid damage by the processes that cause type 1 diabetes in the first place. Semma believes they could help a fraction of patients whose diabetes has different causes.
Semma still has no timeline for when its implantable biotech pancreas could be ready. That means Melton's children will have to wait a while longer. Im sorry it takes so long, says Melton, but it is going to work.
- Diabetes breakthrough: Revolutionary stem cell technique treated 'severe' disease in study - Daily Express - November 22nd, 2021
- The Role of Quality and Speed in Custom Model Generation - FierceBiotech - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Stem cells may be the key to saving white rhinos from extinction - Sciworthy - October 5th, 2021
- Global Allogenic Stem Cell Therapy Market 2021 Size, Share, Growth and Regional Analysis by Segmentation and Country Forecast to 2028 - Digital... - October 5th, 2021
- Human Embryonic Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 The Courier - The Courier - June 8th, 2021
- Conversion of mouse embryonic fibroblasts into neural crest cells and functional corneal endothelia by defined small molecules - Science Advances - June 8th, 2021
- Global Stem Cells Market Regulations and Competitive Landscape Outlook, 2020 to 2025 The Courier - The Courier - June 8th, 2021
- Global cell isolation market was valued at USD7013.71 million in 2020 and is anticipated to reach USD15529.45 million by 2026 - Yahoo Finance - June 8th, 2021
- Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology? - ESHRE - April 4th, 2021
- Human Embryonic Stem Cells (HESC) Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- ESI BIO, Thermo Fisher,... - April 4th, 2021
- New Michigan law requires those receiving Johnson & Johnson vaccine be told it was developed using stem cells | TheHill - The Hill - April 4th, 2021
- Xenobots 2.0 are Here and Still Developed With Frog Stem Cells - Unite.AI - April 4th, 2021
- Global Human Embryonic Stem Cells Industry Market 2021 In-depth Industry Analysis, Growth By 2027:Lonza Group Ltd., Life Technologies Corporation,... - April 4th, 2021
- AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update - Business Wire - April 4th, 2021
- Research Associate in Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 246711 - Times Higher Education (THE) - February 17th, 2021
- Stem Cells Market Size 2021 by Share Growing Rapidly with Recent Trends, Size, Development, Revenue, Demand and Forecast to 2024 NeighborWebSJ -... - February 17th, 2021
- Cell transplant therapy could be a treatment for leading cause of blindness - The Denver Channel - February 17th, 2021
- Cellular Reprogramming Tools Market likely to touch new heights by end of forec - Business-newsupdate.com - February 17th, 2021
- Human Embryonic Stem Cells Market Analysis By Growth ... - February 9th, 2021
- Pros and Cons of embryonic stem cells - Pros an Cons - February 9th, 2021
- Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire - February 9th, 2021
- Reactivation of the pluripotency program precedes formation of the cranial neural crest - Science Magazine - February 4th, 2021
- Should We Double The Age When Science Can Experiment On Babies? - 550 KTSA - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Missouri State Representative Indicted Over Alleged Stem Cell Therapy Scam - IFLScience - February 4th, 2021
- Global Human Embryonic Stem Cells Market increasing demand with Industry Professionalist |know the Brand Players forecast 2027 Jumbo News - Jumbo... - February 4th, 2021
- Push on to Allow Expanded Human-Embryo Research - National Review - February 4th, 2021
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 Murphy's Hockey Law - Murphy's Hockey Law - February 4th, 2021
- Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv... - February 4th, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - January 30th, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 30th, 2021
- Stem Cell Manufacturing includes Attractiveness and Raw Material Analysis and Competitor Position Grid Analysis to 2027 | Merck KGaA, Thermo Fisher... - January 30th, 2021
- RNA Molecules Are Masters of Their Own Destiny Regulating Their Own Production Through a Feedback Loop - SciTechDaily - January 30th, 2021
- The chromosomal protein SMCHD1 regulates DNA methylation and the 2c-like state of embryonic stem cells by antagonizing TET proteins - Science Advances - January 23rd, 2021
- North America to be the Torchbearer to Stem Cell Characterization And Analysis Tools Market NeighborWebSJ - NeighborWebSJ - January 23rd, 2021
- New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health - January 23rd, 2021
- JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modifications - Science Magazine - January 23rd, 2021
- DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities - PRNewswire - January 19th, 2021
- TBC1D3 promotes neural progenitor proliferation by suppressing the histone methyltransferase G9a - Science Advances - January 19th, 2021
- 'He was very honored in his work' - Mercer Island Reporter - December 28th, 2020
- Israeli biotech firm's ALS treatment shows safety of use in trials - The Jerusalem Post - December 16th, 2020
- Ca Bishops To Work w/ Govt on Vaccination Campaigns - Catholic Herald Online - December 14th, 2020
- Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -... - December 6th, 2020
- Stem Cell Market Technology 2021 and Application, Segmentation by Leading Global Players, Market Status by Share and Size Forecast to 2024 - The... - December 6th, 2020
- Stem Cell Therapy Market Size, Opportunities, Dynamic, Outlook and Forecast To 2027 - Cheshire Media - December 6th, 2020
- Stem Cells Market will grow at CAGR of 8.61% by 2027 Cheshire Media - Cheshire Media - December 6th, 2020
- Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego - November 27th, 2020
- Mechanisms of Telomere Protection Are Unique in Stem Cells - Technology Networks - November 27th, 2020
- Stem Cells Market by 2020 Research Report by Manufactures, Types, Applications, Regions and Trends to 2024 | Absolute Reports - The Market Feed - November 25th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 25th, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 25th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 25th, 2020
- Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Yahoo Finance - November 25th, 2020
- Stem Cell Characterization and Analysis Tool Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19... - November 25th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 9th, 2020
- Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly - November 7th, 2020
- Voters asked to approve $5.5 billion for stem cell research - Lebanon Express - November 7th, 2020
- Transcriptional priming as a conserved mechanism of lineage diversification in the developing mouse and human neocortex - Science Advances - November 7th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - PRnews Leader - November 7th, 2020
- U.S. elections bring wins and losses for research community - Science Magazine - November 5th, 2020
- Stem Cell Therapy Market Size, Key Development Trends, and Growth Projection to 2027 - Stock Market Vista - November 5th, 2020
- Global Stem Cells Market 2020 Industry Outlook, Growth, Comprehensive Insights and Forecast 2025 - PRnews Leader - November 5th, 2020
- Panelists debate the implications and ethics of stem cell research - Johns Hopkins News-Letter - October 30th, 2020
- Stem Cell and Regenerative Therapy Market to Remain Balanced During the the COVID-19 Period - re:Jerusalem - October 30th, 2020
- Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center - October 30th, 2020
- Yale New Haven Health Docs: Interpreting the Uptick in Covid-19 Cases - Greenwich Free Press - October 30th, 2020
- Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch - October 29th, 2020
- Outlook for stem cell therapy - its role in tendon regeneration - different treatments for horse tendon injuries - Trainer Magazine - October 29th, 2020
- Yale Health advises against large Thanksgiving gatherings; eastern Connecticut now considered a 'hot spot' - The Westerly Sun - October 29th, 2020
- Stem Cell Therapy Market to Register Unwavering Growth During 2025 - The Think Curiouser - October 29th, 2020
- Human Embryonic Stem Cells (HESC) Market Share, Analysis and In-depth Research on Market Size, Trends, Emerging Growth Factors and Regional Forecasts... - October 20th, 2020
- COVID-19 Analysis to Understand the Competitive Outlook of Human Embryonic Stem Cells (HESC) Market - The Think Curiouser - October 20th, 2020
- Competitive Landscape of Human Embryonic Stem Cells (HESC) Market 2020 | Global Industry Size, Volume, Trends and Revenue Forecast to 2025 - The Think... - October 20th, 2020
- Stem Cells Market 2020 is predicted to rise with a CAGR of XX% by 2026 | Including Growth Prospect, Market Size & Growth, Key Vendors, Top most... - October 20th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 20th, 2020
- Global Stem Cell Manufacturing Market: Industry Analysis and forecast 2019 2027: By Product, Application, End-Users and Region - Stock Market Vista - October 20th, 2020
- The Infodemic: Was Regeneron COVID-19 Treatment Developed Using Stem Cells and Fetal Tissue? - Voice of America - October 15th, 2020
- COVID-19 Impact on Global Human Embryonic Stem Cells Market 2020 Industry Overview, Demand and Insights Analysis Report by 2026 ESI BIO, Thermo... - October 15th, 2020
- Yes on 14 | Mailbox | independentnews.com - Livermore Independent - October 15th, 2020